Nephrons, podocytes and chronic kidney disease: Strategic antihypertensive therapy for renoprotection

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Developmental Biology

Background:

• Chronic kidney disease (CKD) and hypertension share a strong bidirectional relationship, where each condition exacerbates the other.
• Kidney diversity exists, with individuals having lower nephron endowment facing higher risks for CKD and hypertension, aligning with the developmental origins of health and disease theory.
• Nephrons and podocytes, crucial for kidney function, have limited regenerative capacity and decline throughout life.

Purpose of the Study:

• To emphasize the critical link between CKD management and antihypertensive therapy.
• To highlight strategies for preserving nephron and podocyte numbers to slow CKD progression.
• To underscore the importance of individualized treatment approaches for CKD and hypertension.

Main Methods:

• Review of decades of research on kidney physiology and disease.
• Analysis of the relationship between nephron number, podocyte count, and disease progression.
• Synthesis of findings on risk factors, disease mechanisms, and therapeutic strategies.

Main Results:

• Low nephron endowment is a significant risk factor for developing both CKD and hypertension.
• Hypertension contributes to a cycle of podocyte injury, glomerulosclerosis, and nephron loss in CKD.
• Nephron and podocyte numbers are intrinsically linked and essential for maintaining renal function.

Conclusions:

• Maintaining optimal blood pressure and minimizing urinary protein excretion are vital for slowing CKD progression.
• Preserving the number of nephrons and podocytes is a primary strategy for long-term kidney health.
• Individualized lifestyle modifications and antihypertensive therapies are necessary due to kidney diversity.